Andrew W Hahn

Andrew W Hahn

UNVERIFIED PROFILE

Are you Andrew W Hahn?   Register this Author

Register author
Andrew W Hahn

Andrew W Hahn

Publications by authors named "Andrew W Hahn"

Are you Andrew W Hahn?   Register this Author

45Publications

959Reads

12Profile Views

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

Oncologist 2020 Feb 6;25(2):121-e213. Epub 2019 Sep 6.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0599DOI Listing
February 2020

The Role of PD-L1 Testing in Advanced Genitourinary Malignancies.

Eur Urol Focus 2020 Jan 11;6(1):11-13. Epub 2019 Mar 11.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24054569193007
Publisher Site
http://dx.doi.org/10.1016/j.euf.2019.03.003DOI Listing
January 2020

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Eur Urol Oncol 2019 Nov 4;2(6):708-715. Epub 2019 Oct 4.

Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.09.002DOI Listing
November 2019

Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma.

Oncologist 2019 Oct 15. Epub 2019 Oct 15.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0657DOI Listing
October 2019

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.

Cancer Treat Res Commun 2019 6;19:100120. Epub 2019 Feb 6.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive Suite 5726, Salt Lake City, UT 84112, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100120DOI Listing
September 2019

Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.

J Geriatr Oncol 2019 Aug 8. Epub 2019 Aug 8.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.07.002DOI Listing
August 2019

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.

Urol Oncol 2019 06 13;37(6):352.e19-352.e24. Epub 2019 Feb 13.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857455PMC
June 2019

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.

Drugs Aging 2019 05;36(5):395-401

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Suite 2161, Salt Lake City, UT, 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-019-00644-1DOI Listing
May 2019

Germline Variant in and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC).

Mol Cancer Ther 2019 03 26;18(3):726-729. Epub 2018 Dec 26.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0739DOI Listing
March 2019

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome.

Oncologist 2019 02 23;24(2):143-145. Epub 2018 Aug 23.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369955PMC
February 2019

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Curr Treat Options Oncol 2019 02 11;20(2):14. Epub 2019 Feb 11.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0611-zDOI Listing
February 2019

Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis.

J Geriatr Oncol 2019 01 1;10(1):149-154. Epub 2018 Jun 1.

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States. Electronic address:

View Article

Download full-text PDF

Source
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2
Web Search
https://linkinghub.elsevier.com/retrieve/pii/S18794068183008
Publisher Site
http://dx.doi.org/10.1016/j.jgo.2018.05.010DOI Listing
January 2019

Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2018 10 29;16(5):365-368. Epub 2018 May 29.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183028
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.05.001DOI Listing
October 2018

Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2018 08 27;16(4):288-292. Epub 2018 Mar 27.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.03.006DOI Listing
August 2018

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).

World J Oncol 2018 Aug 6;9(4):119-122. Epub 2018 Sep 6.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://www.wjon.org/index.php/WJON/article/view/1144
Publisher Site
http://dx.doi.org/10.14740/wjon1144wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134990PMC
August 2018

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Am Soc Clin Oncol Educ Book 2018 May;38:363-371

From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200967
Publisher Site
http://dx.doi.org/10.1200/EDBK_200967DOI Listing
May 2018

HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer.

JAMA Oncol 2018 04;4(4):562-563

Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.3158DOI Listing
April 2018

The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Curr Treat Options Oncol 2018 02 20;19(2):10. Epub 2018 Feb 20.

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-018-0530-4
Publisher Site
http://dx.doi.org/10.1007/s11864-018-0530-4DOI Listing
February 2018

Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.

Curr Treat Options Oncol 2018 01 24;19(1). Epub 2018 Jan 24.

Department of Oncology, Huntsman Cancer Institute, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0517-1DOI Listing
January 2018

PD-1 checkpoint inhibition: Toxicities and management.

Urol Oncol 2017 12 8;35(12):701-707. Epub 2017 Sep 8.

Department of Internal Medicine, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.08.005DOI Listing
December 2017

Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.

Curr Opin Urol 2017 Nov;27(6):559-565

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00042307-201711000-0001
Publisher Site
http://dx.doi.org/10.1097/MOU.0000000000000443DOI Listing
November 2017

Current Treatment Landscape of Advanced Papillary Renal Cancer.

J Clin Oncol 2017 09 24;35(26):2981-2983. Epub 2017 Jul 24.

Brian Shuch, Yale School of Medicine, New Haven, CT; Andrew W. Hahn, University of Utah School of Medicine, Salt Lake City, UT; and Neeraj Agarwal, University of Utah School of Medicine and Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3328DOI Listing
September 2017

Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.

Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.

Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.08.017DOI Listing
September 2017

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.

JAMA Oncol 2017 06;3(6):856-857

University of Utah Huntsman Cancer Institute, Salt Lake City2Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.0147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824318PMC
June 2017

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy 2017 06;9(8):681-692

Department of Oncology, Huntsman Cancer Institute, Salt Lake City, UT, 84112 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0024DOI Listing
June 2017

9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma.

Med Oncol 2017 05 13;34(5):95. Epub 2017 Apr 13.

University of Tennessee Health Science Center College of Medicine, Memphis, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-017-0957-7DOI Listing
May 2017

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

Mol Clin Oncol 2017 Jan 23;6(1):122-124. Epub 2016 Nov 23.

Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake, UT 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2016.1090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245156PMC
January 2017

Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Hum Vaccin Immunother 2016 12 5;12(12):2997-3004. Epub 2016 Aug 5.

c Huntsman Cancer Institute , Salt Lake City , UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2016.1212794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215367PMC
December 2016

Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.

Anticancer Res 2016 Aug;36(8):4051-5

Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A. Department of Hematology/Oncology, The West Cancer Center, Memphis, TN, U.S.A.

View Article

Download full-text PDF

Source
August 2016

New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.

Med Clin North Am 2016 Jul 16;100(4):911-26. Epub 2016 Apr 16.

Division of Infectious Diseases, University of Washington School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcna.2016.03.012DOI Listing
July 2016

Acute megakaryocytic leukemia: What have we learned.

Blood Rev 2016 Jan 18;30(1):49-53. Epub 2015 Jul 18.

Department of Hematology/Oncology, The West Cancer Center, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.07.005DOI Listing
January 2016

Precision medicine: lessons learned from the SHIVA trial.

Lancet Oncol 2015 Dec;16(16):e580-1

The West Cancer Center, Memphis, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00458-1DOI Listing
December 2015

How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2015 Nov 5;15(11):646-54. Epub 2015 Aug 5.

Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN; Department of Hematology/Oncology, The West Cancer Center, Memphis, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.07.646DOI Listing
November 2015

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.

J Natl Compr Canc Netw 2015 Oct;13(10):1181-5

From the Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee; Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri; and Department of Hematology/Oncology, The West Cancer Center, Memphis, Tennessee. From the Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee; Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri; and Department of Hematology/Oncology, The West Cancer Center, Memphis, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0147DOI Listing
October 2015

Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.

J Neurooncol 2006 Sep 28;79(3):259-70. Epub 2006 Apr 28.

Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-006-9142-0DOI Listing
September 2006